H.C. Wainwright analyst Arthur He CFA maintained a Buy rating on Adagene (ADAG – Research Report) today and set a price target of $8.00.
Arthur He CFA has given his Buy rating due to a combination of factors related to Adagene’s promising clinical developments and financial outlook. The company is advancing its ADG126 program, a monoclonal antibody, in combination with pembrolizumab for treating refractory microsatellite stable colorectal cancer. Recent data presented at a major oncology symposium showed a notable improvement in response rates, which underscores the therapeutic potential of ADG126.
Furthermore, Adagene’s financial position appears stable, with sufficient cash reserves to support operations into the second half of 2026. The company’s strategic plans include discussions with the FDA regarding a regulatory pathway, which could serve as a positive catalyst for the stock if the outcomes are favorable. Additionally, the valuation analysis supports a 12-month price target of $8, based on a risk-adjusted net present value approach, further justifying the Buy rating.
He CFA covers the Healthcare sector, focusing on stocks such as Nektar Therapeutics, LAVA Therapeutics, and Adaptimmune Therapeutics. According to TipRanks, He CFA has an average return of 15.2% and a 43.00% success rate on recommended stocks.